• SB203580 Workflows for p38 MAPK Research

  2026-09-07

  Use SB203580 as a reversible, ATP-competitive probe to connect p38 MAPK activity with epithelial inflammation, neutrophil chemotaxis, and tissue-injury readouts. This workflow translates a periodontitis–COPD mechanism into practical cell-based assays while highlighting dose, timing, solubility, and off-target controls.

• Sulfo-NHS-Biotin for Phage Assay Workflows

  2026-09-07

  Sulfo-NHS-Biotin adds covalent, aqueous-compatible labeling to workflows that investigate bacterial surfaces, phage binding, and protein capture. Combined thoughtfully with phage-layer interferometry, it can provide orthogonal biochemical context without confusing receptor labeling with proof of infectivity.

• Freeze-Driven Betaine Loading Improves mRNA Delivery

  2026-09-05

  The reference study shows that freezing can do more than preserve lipid nanoparticles: freeze concentration drives betaine into the particles, where it improves endosomal escape and mRNA delivery. This formulation concept increased reporter expression and strengthened immune responses in female mice, while also suggesting a route toward dose-sparing mRNA systems.

• Biotin-16-UTP: From RNA Mechanism to Translation

  2026-09-04

  A thought-leadership guide to using Biotin-16-UTP as an affinity-enabled RNA labeling strategy for mechanistic studies of lncRNA biology, including the LINC02870–EIF4G1–SNAIL axis in hepatocellular carcinoma. The article connects assay design, validation, translational relevance, and practical limitations.

• A-1210477: Translating MCL-1 Dependence

  2026-09-04

  MCL-1 inhibitor A-1210477 offers a focused way to interrogate BIM sequestration, mitochondrial apoptosis, and cancer cell survival regulation in MCL-1-dependent models. This thought-leadership guide connects mechanistic biology with assay design, combination strategy, and translational decision-making while clearly defining the compound’s in vivo limitations.

• Z-IETD-FMK Workflows for Caspase-8 Research

  2026-09-04

  Z-IETD-FMK enables targeted dissection of caspase-8 in activated T cells, TRAIL-responsive cancer models, and time-resolved cell-death assays. Its value is greatest when paired with vehicle controls, orthogonal apoptosis readouts, and growth-versus-death analysis rather than used as a stand-alone viability reagent.

• Regorafenib, RRM2, and Melanoma Progression

  2026-09-03

  The 2024 iScience study identifies RRM2 as a functional downstream mediator of Regorafenib activity in melanoma and connects this response to ERK/E2F3 signaling. Its combination of melanoma cell assays, RNA sequencing, rescue experiments, and in vivo validation provides a mechanistic framework for studying BAY 73-4506 beyond its established multikinase effects.

• EGCG Analogs Target Intracellular Staphylococcus aureus

  2026-09-02

  Grosso and colleagues designed EGCG analogs with improved stability and membrane permeability while preserving or enhancing antistaphylococcal activity. MCC-1 and MCC-2 were more active against extracellular Staphylococcus aureus, restored β-lactam susceptibility in MRSA, and supported macrophage- and antibiotic-mediated clearance of intracellular bacteria.

• Triamcinolone B1859: Practical Research Guide

  2026-09-02

  Triamcinolone B1859 is a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock handling, storage, assay controls, and interpretation boundaries; the compound is not intended for diagnostic, therapeutic, or clinical use.

• MCL-1’s Canonical Role in Breast Cancer

  2026-09-01

  Campbell and colleagues show that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK-mediated mitochondrial cell death. Genetic deletion and pharmacological inhibition both impaired tumor growth, while removal of BAX and BAK prevented these effects, providing a mechanistic rationale for apoptosis-focused MCL-1 inhibitor research.

• ABT-263 (Navitoclax): From Priming to Proof

  2026-09-01

  A translational framework for using ABT-263 (Navitoclax) to connect Bcl-2 family dependence, mitochondrial priming, caspase activation, and emerging evidence that Pol II degradation can trigger cell death independently of transcriptional loss.

• Sabutoclax for Reliable Apoptosis Assays

  2026-08-31

  Learn how Sabutoclax, SKU A4199, can improve interpretation of viability, proliferation, and cytotoxicity assays by linking concentration–response data with orthogonal apoptosis measurements. This scenario-based guide covers assay design, formulation, controls, data interpretation, and practical supplier selection.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-08-31

  This case report describes radiologic reduction of metastatic lymph nodes in intra-abdominal desmoplastic small round cell tumor after anlotinib treatment, providing the first published clinical signal for this otherwise poorly standardized disease. Its main value is hypothesis generation: it connects a multi-target tyrosine kinase inhibitor with a rare, aggressive sarcoma while clearly requiring validation in larger and controlled studies.

• Firefly Luciferase mRNA: A Systems Assay Guide

  2026-08-30

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a luminescent reporter: its chemistry, handling, delivery vehicle, and substrate exposure jointly determine assay quality. This guide connects transcript design with freeze–thaw formulation science to improve experimental interpretation and reproducibility.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-08-29

  HyperPFU™ high-fidelity DNA polymerase is a proofreading DNA polymerase for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult templates. It is appropriate for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or polymerase-generated sticky ends.

8034 records 1/536 page Next 12345 下5页 Last page